Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review

被引：5
作者：
Duperrouzel, Corinne [1 ]
Martin, Coby [1 ]
Mendell, Ari [1 ]
Bourque, Megan [1 ]
Carrera, Adam [2 ]
Mack, Alicia [1 ]
Nesheim, Jeffrey [2 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Urovant Sci, Irvine, CA 92617 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2022年 / 11卷 / 18期
关键词：
anticholinergic; anticholinergic burden; antimuscarinic; economic burden; HCRU; healthcare costs; healthcare resource utilization; incontinence; overactive bladder; urology; QUALITY-OF-LIFE; EXTENDED-RELEASE TOLTERODINE; COST-EFFECTIVENESS; RESOURCE UTILIZATION; UNITED-STATES; URINARY-INCONTINENCE; WORK PRODUCTIVITY; NERVE-STIMULATION; MEDICATION USE; IMPACT;
D O I：
10.2217/cer-2022-0160
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To determine the economic burden associated with anticholinergic medication use in adults with overactive bladder (OAB) in the USA. Methods: A systematic literature review was conducted to identify articles assessing healthcare resource utilization (HCRU) and costs associated with anticholinergic use in adults with OAB. Results: From the 34 articles identified, increased anticholinergic burden, switching anticholinergic treatments and potentially inappropriate anticholinergic use were associated with increased HCRU and/or costs. However, studies comparing patients with OAB receiving anticholinergics to individuals with untreated OAB or without OAB reported a mix of increases and decreases in HCRU and costs. Conclusion: Additional controlled studies assessing the economic impact of anticholinergics in OAB are needed and may enable optimization of economic and potentially patient outcomes.
引用
收藏
页码：1375 / 1394
页数：20
相关论文
共 68 条
  • [1] 2018 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (03) : 367 - 425
  • [2] Arikian S R, 2000, Manag Care Interface, V13, P88
  • [3] Armstrong Edward P, 2012, J Med Econ, V15 Suppl 1, P35, DOI 10.3111/13696998.2012.732635
  • [4] Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: A longitudinal cohort study
    Balkrishnan, R
    Bhosle, MJ
    Camacho, FT
    Anderson, RT
    [J]. JOURNAL OF UROLOGY, 2006, 175 (03) : 1067 - 1071
  • [5] Patient-reported reasons for discontinuing overactive bladder medication
    Benner, Joshua S.
    Nichol, Michael B.
    Rovner, Eric S.
    Jumadilova, Zhanna
    Alvir, Jose
    Hussein, Mohamed
    Fanning, Kristina
    Trocio, Jeffrey N.
    Brubaker, Linda
    [J]. BJU INTERNATIONAL, 2010, 105 (09) : 1276 - 1282
  • [6] An international registry of systematic-review protocols
    Booth, Alison
    Clarke, Mike
    Ghersi, Davina
    Moher, David
    Petticrew, Mark
    Stewart, Lesley
    [J]. LANCET, 2011, 377 (9760) : 108 - 109
  • [7] Campbell NL, 2021, J AM GERIATR SOC, V69, pS139
  • [8] Campbell NL, 2013, J AM GERIATR SOC, V61, pS142
  • [9] Cost-Effectiveness of Percutaneous Tibial Nerve Stimulation Versus Extended Release Tolterodine for Overactive Bladder
    Chen, Heidi W.
    Bercik, Richard S.
    Werner, Erika F.
    Thung, Stephen F.
    [J]. JOURNAL OF UROLOGY, 2012, 187 (01) : 178 - 184
  • [10] Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
    Coupland, Carol A. C.
    Hill, Trevor
    Dening, Tom
    Morriss, Richard
    Moore, Michael
    Hippisley-Cox, Julia
    [J]. JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1084 - 1093
1234567